Oebisu Naoto, Hoshi Manabu, Ieguchi Makoto, Takada Jun, Iwai Tadashi, Ohsawa Masahiko, Nakamura Hiroaki
Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine, Abeno-Ku, Osaka 545‑8585, Japan.
Department of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Abeno-Ku, Osaka 545‑8585, Japan.
Oncol Rep. 2014 Oct;32(4):1654-60. doi: 10.3892/or.2014.3378. Epub 2014 Aug 4.
Resolution of ultrasonography (US) has undergone marked development. Additionally, a new-generation contrast medium (Sonazoid) used for US is newly available. Contrast-enhanced US has been widely used for evaluating several types of cancer. In the present study, we evaluated the ability of color Doppler US (CDUS) and Sonazoid to differentiate between benign and malignant soft tissue tumors. A total of 180 patients (87 male, 93 female) were enrolled in the present study. The patient ages ranged from 1 to 91 years (mean 58.1±20.0 years). The maximum size, depth, tumor margins, shape, echogenicity and textural pattern were measured on gray-scale images. CDUS was used to evaluate the intratumoral blood flow with and without Sonazoid. Peak systolic flow velocity (Vp), mean flow velocity (Vm), resistivity index (RI) and pulsatility index (PI) of each detected intratumoral artery were automatically calculated with power Doppler US (PDUS). The present study included 118 benign and 62 malignant tumors. Statistical significances were found in size, depth, tumor margin and textural pattern but not in shape or echogenicity on gray-scale images. Before Sonazoid injection, CDUS findings showed 55% sensitivity, 77% specificity and 69% accuracy, whereas contrast-enhanced CDUS showed 87% sensitivity, 68% specificity and 74% accuracy. There were no statistically significant differences between malignant and benign tumors regarding the mean Vp, Vm, RI and PI values determined on PDUS. In conclusion, contrast-enhanced CDUS proved to be a reliable diagnostic tool for detecting malignant potential in soft tissue tumors.
超声检查(US)的分辨率有了显著提高。此外,一种用于超声检查的新一代造影剂(声诺维)已全新上市。超声造影已广泛应用于多种癌症的评估。在本研究中,我们评估了彩色多普勒超声(CDUS)和声诺维区分良性和恶性软组织肿瘤的能力。本研究共纳入180例患者(男性87例,女性93例)。患者年龄范围为1至91岁(平均58.1±20.0岁)。在灰阶图像上测量肿瘤的最大尺寸、深度、边界、形状、回声性和纹理模式。使用CDUS评估使用声诺维和不使用声诺维时肿瘤内的血流情况。通过功率多普勒超声(PDUS)自动计算每个检测到的肿瘤内动脉的收缩期峰值流速(Vp)、平均流速(Vm)、阻力指数(RI)和搏动指数(PI)。本研究包括118例良性肿瘤和62例恶性肿瘤。在灰阶图像上,肿瘤的大小、深度、边界和纹理模式存在统计学差异,但形状或回声性无差异。在注射声诺维之前,CDUS检查结果的敏感性为55%,特异性为77%,准确性为69%;而超声造影增强CDUS的敏感性为87%,特异性为68%,准确性为74%。PDUS测定的恶性肿瘤和良性肿瘤的平均Vp、Vm、RI和PI值之间无统计学显著差异。总之,超声造影增强CDUS被证明是检测软组织肿瘤恶性潜能的可靠诊断工具。